Q+A: Blackstone's BioMed on UK growth, COVID-19 and how demand for life sciences space is changing

11 Feb 2021 | 08:18 GMT | by Guy Montague-Jones

Across BioMed's portfolio 48% of tenants are working on a COVID treatment, test or vaccine

Want to read the full article?

You must be a subscriber to read this article.

Please Login or Subscribe

Related Articles